RT Journal Article
SR Electronic
T1 The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.26.23296186
DO 10.1101/2023.09.26.23296186
A1 Dutcher, Ethan G.
A1 Epel, Elissa S.
A1 Mason, Ashley E.
A1 Hecht, Frederick M.
A1 Robinson, James E.
A1 Drury, Stacy S.
A1 Prather, Aric A.
YR 2023
UL http://medrxiv.org/content/early/2023/10/06/2023.09.26.23296186.abstract
AB Protection against SARS-CoV-2 wanes over time, and booster uptake has been low, in part because of concern about side effects. We examined the relationships between local and systemic symptoms, biometric changes, and neutralizing antibodies (nAB) after mRNA vaccination. Data were collected from adults (n = 364) who received two doses of either BNT162b2 or mRNA-1273. Serum nAB concentration was measured at 1 and 6 months post-vaccination. Daily symptom surveys were completed for six days starting on the day of each dose. Concurrently, objective biometric measurements, including skin temperature, heart rate, heart rate variability, and respiratory rate, were collected. We found that certain symptoms (chills, tiredness, feeling unwell, and headache) after the second dose were associated with increases in nAB at 1 and 6 months post-vaccination, to roughly 140-160% the level of individuals without each symptom. Each additional symptom predicted a 1.1-fold nAB increase. Greater increases in skin temperature and heart rate after the second dose predicted higher nAB levels at both time points, but skin temperature change was more predictive of durable (6 month) nAB response than of short-term (1 month) nAB response. In the context of low ongoing vaccine uptake, our convergent symptom and biometric findings suggest that public health messaging could seek to reframe systemic symptoms after vaccination as desirable.Competing Interest StatementAEM has received remuneration from Oura Health for consulting. AAP is an advisor to NeuroGeneces and L-New Co. ESE is on the scientific advisory boards of Meru Health and Oura Health.Funding StatementThe project was supported by funding from the National Institutes of Health (R24AG048024, 5U24AG066528, and U54CA260581).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board (IRB) of University of California, San Francisco (UCSF) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors